Enhanced ROS Production and Mitochondrial Metabolic Shifts in CD4 + T Cells of an Autoimmune Uveitis Model.

Autor: Söth, Ronja¹ (AUTHOR), Hoffmann, Anne L. C.¹ (AUTHOR), Deeg, Cornelia A.¹ (AUTHOR) cornelia.deeg@lmu.de

Publikováno v: International Journal of Molecular Sciences. Nov2024, Vol. 25 Issue 21, p11513. 16p.

Intratumoral Injection of Clostridium novyi -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors.

Autor: Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org khazaie@mayo.edu gounderm@mskcc.org., Zhang HH; BioMed Valley Discoveries Inc., Kansas City, Missouri., Pezeshki A; Department of Immunology, Mayo Clinic, Rochester, Minnesota., Goel S; Montefiore/Albert Einstein Cancer Center, Bronx, New York., Murthy R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang-Gillam A; Washington University in St. Louis, St. Louis, Missouri., Shepard DR; Cleveland Clinic, Cleveland, Ohio., Helgason T; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Masters T; Early Drug Development Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Klang M; Early Drug Development Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Huang SY; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sakamuri D; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Raina A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Torrisi J; Early Drug Development Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Solomon SB; Early Drug Development Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Weissfeld A; Microbiology Specialists Inc., Houston, Texas., Trevino E; Microbiology Specialists Inc., Houston, Texas., DeCrescenzo G; BioMed Valley Discoveries Inc., Kansas City, Missouri., Collins A; BioMed Valley Discoveries Inc., Kansas City, Missouri., Miller M; BioMed Valley Discoveries Inc., Kansas City, Missouri., Salstrom JL; PAREXEL International, Waltham, Massachusetts., Korn RL; Imaging Endpoints, Scottsdale, Arizona., Zhang L; BioMed Valley Discoveries Inc., Kansas City, Missouri., Saha S; BioMed Valley Discoveries Inc., Kansas City, Missouri.; Atlas Venture, Boston, Massachusetts., Leontovich AA; Biomedical Informatics, Mayo Clinic, Rochester, Minnesota., Tung D; BioMed Valley Discoveries Inc., Kansas City, Missouri., Kreider B; BioMed Valley Discoveries Inc., Kansas City, Missouri., Varterasian M; BioMed Valley Discoveries Inc., Kansas City, Missouri., Khazaie K; Department of Immunology, Mayo Clinic, Rochester, Minnesota. fjanku@mdanderson.org khazaie@mayo.edu gounderm@mskcc.org., Gounder MM; Early Drug Development Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York. fjanku@mdanderson.org khazaie@mayo.edu gounderm@mskcc.org.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jan 01; Vol. 27 (1), pp. 96-106. Date of Electronic Publication: 2020 Oct 12.

A solid-state amorphous selenium avalanche technology for low photon flux imaging applications

Autor: Wronski, M. M., Zhao, W., Reznik, A., Tanioka, K., DeCrescenzo, G., Rowlands, J. A.

The feasibility of a practical solid-state technology for low photon flux imaging applications was investigated. The technology is based on an amorphous selenium photoreceptor with a voltage-controlled avalanche multiplication gain. If this photorece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2c59eaa7e79fcbaa6252e180d62e3e37
https://europepmc.org/articles/PMC2945739/

Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release.

Autor: Szot C; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA., Saha S; BioMed Valley Discoveries Inc., Kansas City, Missouri, USA., Zhang XM; BioMed Valley Discoveries Inc., Kansas City, Missouri, USA., Zhu Z; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA.; Protein Interactions Section, Cancer and Inflammation Program, NCI, NIH, Frederick, Maryland, USA., Hilton MB; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA.; Basic Research Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research (FNLCR), Frederick, Maryland, USA., Morris K; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA.; Basic Research Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research (FNLCR), Frederick, Maryland, USA., Seaman S; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA., Dunleavey JM; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA., Hsu KS; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA., Yu GJ; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA., Morris H; Transgenic Core Facility, MCGP, NCI, Frederick, Maryland, USA., Swing DA; Transgenic Core Facility, MCGP, NCI, Frederick, Maryland, USA., Haines DC; Veterinary Pathology Section, Pathology/Histotechnology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, Maryland, USA., Wang Y; Protein Interactions Section, Cancer and Inflammation Program, NCI, NIH, Frederick, Maryland, USA., Hwang J; Protein Interactions Section, Cancer and Inflammation Program, NCI, NIH, Frederick, Maryland, USA., Feng Y; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA.; Protein Interactions Section, Cancer and Inflammation Program, NCI, NIH, Frederick, Maryland, USA., Welsch D; BioMed Valley Discoveries Inc., Kansas City, Missouri, USA., DeCrescenzo G; BioMed Valley Discoveries Inc., Kansas City, Missouri, USA., Chaudhary A; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA., Zudaire E; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA., Dimitrov DS; Protein Interactions Section, Cancer and Inflammation Program, NCI, NIH, Frederick, Maryland, USA., St Croix B; Tumor Angiogenesis Unit, Mouse Cancer Genetics Program (MCGP), National Cancer Institute (NCI), NIH, Frederick, Maryland, USA.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2018 Jul 02; Vol. 128 (7), pp. 2927-2943. Date of Electronic Publication: 2018 Jun 04.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.